In this issue:
MRD eradication with clofarabine vs. high-dose cytarabine in B-precursor ALL
Ivosidenib and azacitidine in IDH1-mutated AML
Health-related QOL in indolent non-Hodgkin lymphoma survivors
Timing of high-dose methotrexate CNS prophylaxis in DLBCL
Risk factors for neurocognitive and psychosocial problems after Hodgkin lymphoma
Sex-based disparities in paediatric ALL outcomes
Zanubrutinib in relapsed/refractory MCL
Long-term morbidity in stage I–IIA Hodgkin lymphoma treated with ABVD and limited-field radiotherapy
Older patients with previously untreated advanced-stage classical Hodgkin lymphoma
PET2 response associated with survival in newly diagnosed DLBCL
Please login below to download this issue (PDF)